Intravenous immune globulin suppresses angiogenesis in mice and humans

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F16%3A00077910" target="_blank" >RIV/00023001:_____/16:00077910 - isvavai.cz</a>

Result on the web

<a href="https://www.nature.com/articles/sigtrans20152.pdf" target="_blank" >https://www.nature.com/articles/sigtrans20152.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/sigtrans.2015.2" target="_blank" >10.1038/sigtrans.2015.2</a>

Result language

angličtina

Original language name

Intravenous immune globulin suppresses angiogenesis in mice and humans

Original language description

Human intravenous immune globulin (IVIg), a purified IgG fraction composed of similar to 60% IgG1 and obtained from the pooled plasma of thousands of donors, is clinically used for a wide range of diseases. The biological actions of IVIg are incompletely understood and have been attributed both to the polyclonal antibodies therein and also to their IgG (IgG) Fc regions. Recently, we demonstrated that multiple therapeutic human IgG1 antibodies suppress angiogenesis in a target-independent manner via FcyRI, a high-affinity receptor for IgG1. Here we show that IVIg possesses similar anti-angiogenic activity and inhibited blood vessel growth in five different mouse models of prevalent human diseases, namely, neovascular age-related macular degeneration, corneal neovascularization, colorectal cancer, fibrosarcoma and peripheral arterial ischemic disease. Angioinhibition was mediated by the Fc region of IVIg, required FcyRl and had similar potency in transgenic mice expressing human FcyRs. Finally, IVIg therapy administered to humans for the treatment of inflammatory or autoimmune diseases reduced kidney and muscle blood vessel densities. These data place IVIg, an agent approved by the US Food and Drug Administration, as a novel angioinhibitory drug in doses that are currently administered in the clinical setting. In addition, they raise the possibility of an unintended effect of IVIg on blood vessels.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

10608 - Biochemistry and molecular biology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2016

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Signal Transduction and Targeted Therapy

ISSN

2095-9907

e-ISSN

—

Volume of the periodical

1

Issue of the periodical within the volume

28 January 2016

Country of publishing house

GB - UNITED KINGDOM

Number of pages

8

Pages from-to

"art. no. 15002"

UT code for WoS article

000454602900002

EID of the result in the Scopus database

2-s2.0-85043614237